Risankizumab
| Risankizumab (ABBV-066) is an
anti-IL-23 antibody being investigated for the treatment of
multiple inflammatory diseases, including psoriasis, Crohn's
disease, ulcerative colitis, atopic dermatitis psoriatic
arthritis and Hidradenitis Suppurativa. |
Type of Molecule
BiologicTarget
IL-23Product Type
New Indication| Potential Indication | Region | Phase (1, 2, 3, Submitted) |
|---|---|---|
| Atopic Dermatitis | n/a |
Phase 2
|
| Crohn's Disease | n/a |
Phase 3
|
| Psoriatic Arthritis | n/a |
Phase 3
|
| Psoriasis | US, EU |
Approved
|
| Ulcerative Colitis | n/a |
Phase 3
|
| Hidradenitis Suppurativa | n/a |
Phase 2
|